Emerging applications of gene edited T cells for the treatment of leukemia

The first applications of gene-edited T cells are reaching clinical phase testing as new reagents including TALENs and CRISPR/Cas9 nucleases have emerged to allow efficient and highly specific cell engineering. The transplant setting is an ideal testing ground for these new therapies, given the established infrastructure for cell based interventions. Powerful new immunotherapies are anticipated, which will need to be evaluated in carefully...